Ardelyx, a US-based healthcare company to treat dietary problems, has raised $30m in its series B round from a consortium including a new investor, Amgen Ventures, the corporate venturing unit of the eponymous drugs maker.
Alongside Amgen Ventures, which was founded in 2004, in the B round were venture capital firms NEA and CMEA and individual investors.
NEA and CMEA had previously invested in Ardelyx’s $26m A round in June 2008, according to data provider VentureDeal.
The B round will be used for Ardelyx’s pipeline that includes three product candidates: a clinical stage product, RDX5791, being evaluated in constipation-predominant irritable bowel syndrome (IBS-C) and in the prevention of excess dietary sodium absorption, and two preclinical products, RDX002 in chronic kidney disease and RDX009 in type 2 diabetes.